Abstract
One of the major hurdles facing cancer immunotherapy is that cancers may downregulate expression of MHC class I molecules. The development of a suitable tumor model with downregulated MHC class I expression is critical for designing vaccines and immunotherapeutic strategies to control such tumors. We developed an E7-expressing murine tumor model with downregulated MHC class I expression, TC-1 P3 (A15). Using this model, we tested DNA and vaccinia vaccines for their ability to control tumors with downregulated MHC class I expression. We found that vaccination with DNA encoding E7 linked to Mycobacterial heat shock protein 70 (HSP70) generated a significant antitumor effect against TC-1 P3 (A15), while vaccination with E7/HSP70 vaccinia did not generate an appreciable antitumor effect. Lymphocyte depletion experiments revealed that both CD8+ T cells and NK cells were essential for the antitumor effect generated by E7/HSP70 DNA against TC-1 P3 (A15). Furthermore, tumor protection experiments using IFN-γ knockout mice revealed that IFN-γ was essential for the antitumor effect generated by E7/HSP70 DNA against TC-1 P3 (A15). Our results demonstrate that vaccination with E7/HSP70 DNA results in a significant antitumor effect against a neoplasm with downregulated MHC class I expression and the importance of CD8+ T cells, NK cells, and IFN-γ in generating this antitumor effect.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Chen CH, Wu TC . Experimental vaccine strategies for cancer immunotherapy. J Biomed Sci 1998; 5: 231.
Restifo NP et al. Identification of human cancers deficient in antigen processing. J Exp Med 1993; 177: 265.
Ferrone S, Marincola FM . Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol Today 1995; 16: 487.
Korkolopoulou P et al. Loss of antigen-presenting molecules (MHC class I and TAP-1) in lung cancer. Br J Cancer 1996; 73: 148.
Sanda MG et al. Molecular characterization of defective antigen processing in human prostate cancer. J Natl Cancer Inst 1995; 87: 280.
Vitale M et al. HLA class I antigen and transporter associated with antigen processing (TAP1 and TAP2) down-regulation in high-grade primary breast carcinoma lesions. Cancer Res 1998; 58: 737.
Vegh Z, Wang P, Vanky F, Klein E . Selectively down-regulated expression of major histocompatibility complex class I alleles in human solid tumors. Cancer Res 1993; 53: 2416.
Koopman LA et al. Multiple genetic alterations cause frequent and heterogeneous human histocompatibility leukocyte antigen class I loss in cervical cancer. J Exp Med 2000; 191: 961.
Sherritt M et al. Immunization with tumor-associated epitopes fused to an endoplasmic reticulum translocation signal sequence affords protection against tumors with down-regulated expression of MHC and peptide transporters. Int Immunol 2001; 13: 265.
Wu T-C et al. Engineering an intracellular pathway for MHC class II presentation of HPV-16 E7. Proc Natl Acad Sci 1995; 92: 11671.
Ji H et al. Targeting HPV-16 E7 to the endosomal/lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine HPV-16 E7-expressing tumors. Hum Gene Ther 1999; 10: 2727.
Lin K-Y et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 1996; 56: 21.
Condon C et al. DNA-based immunization by in vivo transfection of dendritic cells. Nat Med 1996; 2: 1122.
Chen C-H et al. Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. Cancer Res 2000; 60: 1035.
Hung CF et al. Enhancement of DNA vaccine potency by linkage of antigen gene to a gene encoding the extracellular domain of Fms-like tyrosine kinase 3-ligand. Cancer Res 2001; 61: 1080.
Hung C-F et al. Cancer immunotherapy using a DNA vaccine encoding the translocation domain of a bacterial toxin linked to a tumor antigen. Cancer Res 2001; 61: 3698.
Chen CH et al. Recombinant DNA vaccines protect against tumors that are resistant to recombinant vaccinia vaccines containing the same gene. Gene Ther 2001; 8: 128.
Zeh III HJ et al. High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J Immunol 1999; 162: 989.
Dutoit V et al. Heterogeneous T-cell response to MAGE-A10(254–262): high avidity-specific cytolytic T lymphocytes show superior antitumor activity. Cancer Res 2001; 61: 5850.
Savage PA, Boniface JJ, Davis MM . A kinetic basis for T cell receptor repertoire selection during an immune response. Immunity 1999; 10: 485.
Weber JS, Rosenberg SA . Modulation of murine tumor major histocompatibility antigens by cytokines in vivo and in vitro. Cancer Res 1988; 48: 5818.
Slifka MK, Whitton JL . Functional avidity maturation of CD8+ T cells without selection of higher affinity TCR. Nat Immunol 2001; 2: 711.
Margulies DH . TCR avidity: it's not how strong you make it, it's how you make it strong. Nat Immunol 2001; 2: 669.
Fahmy TM, Bieler JG, Edidin M, Schneck JP . Increased TCR avidity after T cell activation: a mechanism for sensing low-density antigen. Immunity 2001; 14: 135.
Derby MA, Wang J, Margulies DH, Berzofsky JA . Two intermediate-avidity cytotoxic T lymphocyte clones with a disparity between functional avidity and MHC tetramer staining. Int Immunol 2001; 13: 817.
Alexander-Miller MA, Leggatt GR, Berzofsky JA . Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc Natl Acad Sci USA 1996; 93: 4102.
Derby M, Alexander-Miller M, Tse R, Berzofsky J . High-avidity CTL exploit two complementary mechanisms to provide better protection against viral infection than low-avidity CTL. J Immunol 2001; 166: 1690.
Seliger B, Maeurer MJ, Ferrone S . TAP off – tumors on. Immunol Today 1997; 18: 292.
Porgador A, Mandelboim O, Restifo NP, Strominger JL . Natural killer cell lines kill autologous beta2-microglobulin-deficient melanoma cells: implications for cancer immunotherapy. Proc Natl Acad Sci USA 1997; 94: 13140.
Multhoff G et al. Heat shock protein 70 (Hsp70) stimulates proliferation and cytolytic activity of natural killer cells. Exp Hematol 1999; 27: 1627.
Dighe AS, Richards E, Old LJ, Schreiber RD . Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. Immunity 1994; 1: 447.
Kaplan DH et al. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA 1998; 95: 7556.
Seliger B, Pfizenmaier K . Post-transcriptional downregulation of MHC class I expression in oncogene-transformed cells is reverted by IFN-gamma and TNF-alpha. J Immunogenet 1989; 16: 315.
Klinman DM, Yamshchikov G, Ishigatsubo Y . Contribution of CpG motifs to the immunogenicity of DNA vaccines. J Immunol 1997; 158: 3635.
Sparwasser T et al. Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells. Eur J Immunol 1998; 28: 2045.
Jakob T et al. Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: a role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA. J Immunol 1998; 161: 3042.
Ballas ZK, Rasmussen WL, Krieg AM . Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J Immunol 1996; 157: 1840.
Alcami A, Smith GL . Vaccinia, cowpox, and camelpox viruses encode soluble gamma interferon receptors with novel broad species specificity. J Virol 1995; 69: 4633.
Alcami A, Smith GL . Soluble interferon-gamma receptors encoded by poxviruses. Comp Immunol Microbiol Infect Dis 1996; 19: 305.
Symons JA, Alcami A, Smith GL . Vaccinia virus encodes a soluble type I interferon receptor of novel structure and broad species specificity. Cell 1995; 81: 551.
Smith GL et al. Vaccinia virus immune evasion. Immunol Rev 1997; 159: 137.
Restifo NP et al. Molecular mechanisms used by tumors to escape immune recognition: immunogenetherapy and the cell biology of major histocompatibility complex class I. J Immunother 1993; 14: 182.
Walter W et al. MHC class II antigen presentation pathway in murine tumours: tumour evasion from immunosurveillance? Br J Cancer 2000; 83: 1192.
Zheng P, Sarma S, Guo Y, Liu Y . Two mechanisms for tumor evasion of preexisting cytotoxic T-cell responses: lessons from recurrent tumors. Cancer Res 1999; 59: 3461.
Seliger B, Maeurer MJ, Ferrone S . Antigen-processing machinery breakdown and tumor growth. Immunol Today 2000; 21: 455.
Johnsen AK, Templeton DJ, Sy M, Harding CV . Deficiency of transporter for antigen presentation (TAP) in tumor cells allows evasion of immune surveillance and increases tumorigenesis. J Immunol 1999; 163: 4224.
Hahne M et al. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science 1996; 274: 1363.
Nagata S . Fas ligand and immune evasion. Nat Med 1996; 2: 1306.
Strand S et al. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells – a mechanism of immune evasion? Nat Med 1996; 2: 1361.
Edward M . Integrins and other adhesion molecules involved in melanocytic tumor progression. Curr Opin Oncol 1995; 7: 185.
Chouaib S et al. The host-tumor immune conflict: from immunosuppression to resistance and destruction. Immunol Today 1997; 18: 493.
Moss B, Earl P . Overview of the vaccinia virus expression system. Curr Prot Mol Biol, 2001; 3: 16.15.1.
Earl P, Moss B . Preparation of cell cultures and vaccinia virus stocks. Curr Prot Mol Biol, 2001; 3: 16.16.1.
Earl P, Moss B . Generation of recombinant vaccinia viruses. Curr Prot Mol Biol, 2001; 3: 16.17.1.
Ji H et al. Antigen-specific immunotherapy for murine lung metastatic tumors expressing human papillomavirus type 16 E7 oncoprotein. Int J Cancer 1998; 78: 41.
Chen CH et al. Gene gun-mediated DNA vaccination induces antitumor immunity against human papillomavirus type 16 E7-expressing murine tumor metastases in the liver and lungs. Gene Ther 1999; 6: 1972.
Feltkamp MC et al. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol 1993; 23: 2242.
Acknowledgements
We thank Drs Robert Kurman, Drew Pardoll, and Hyam Levitsky for helpful discussions. We also thank Drs Richard Roden and Ralph Hruban for a critical review of the manuscript. We thank The Tetramer Core Facility at NIH for providing PE-labeled E7 (aa 49–57) peptide-H2-Db tetramer. Dr Wen-Fang Cheng (RE88P005) is a recipient of the NHRI physician scientist fellowship award. Dr Cheng is supported by National Science Committee of Taiwan (NSC91-2341-B-002-369) and National Taiwan University Hospital (NTUH 91-F002). Ken-Yu Lin is a Howard Hughes predoctoral fellow.
This work was supported by NIH 5 PO1 34582-01, U19 CA72108-02, RO1 CA72631-01, RO1 CA83706-01, PO1AI48203-01, and American Cancer Society.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Cheng, W., Hung, C., Lin, K. et al. CD8+ T cells, NK cells and IFN-γ are important for control of tumor with downregulated MHC class I expression by DNA vaccination. Gene Ther 10, 1311–1320 (2003). https://doi.org/10.1038/sj.gt.3301982
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.gt.3301982
Keywords
This article is cited by
-
NANOG signaling promotes metastatic capability of immunoedited tumor cells
Clinical & Experimental Metastasis (2015)
-
Control of HPV-associated tumors by innovative therapeutic HPV DNA vaccine in the absence of CD4+ T cells
Cell & Bioscience (2014)
-
DNA vaccine elicits an efficient antitumor response by targeting the mutant Kras in a transgenic mouse lung cancer model
Gene Therapy (2014)
-
In vivo comparison of local versus systemic delivery of immunostimulating siRNA in HPV‐driven tumours
Immunology & Cell Biology (2014)
-
Intratumoral injection of therapeutic HPV vaccinia vaccine following cisplatin enhances HPV-specific antitumor effects
Cancer Immunology, Immunotherapy (2013)